Estimated Cost Impact on Public Healthcare System from Adding Risdiplam on List of Subsidised Drugs

41 Mr Ong Hua Han asked the Minister for Health how does the Ministry's Drug Advisory Committee derive the estimated cost impact to the public healthcare system of listing risdiplam on the List of Subsidised Drugs to be between $5 million and $10 million per year in the first five years.

Mr Ong Ye Kung: The question has been addressed in my Oral reply to Parliamentary Questions Nos 97 and 98 on the Order Paper for 2 July 2024. [Please refer to "Annual Cost of Taking Risdiplam for Treatment of Spinal Muscular Atrophy and Decisions on Drug Advisory Committee Recommendations", Official Report, 2 July 2024, Vol 95, Issue 137, Written Answers to Questions for Oral Answer not Answered by End of Question Time section.]